Stockscreener 앱 받기
91.88
1.47%
-1.37
전일 마감가:
$93.25
열려 있는:
$92.65
하루 거래량:
1.13M
Relative Volume:
1.03
시가총액:
$9.86B
수익:
$769.10M
순이익/손실:
$46.67M
주가수익비율:
262.51
EPS:
0.35
순현금흐름:
$119.79M
1주 성능:
+1.85%
1개월 성능:
+17.61%
6개월 성능:
+145.01%
1년 성능:
+27.59%
1일 변동 폭
$90.02
$93.17
1주일 범위
$89.73
$95.11
52주 변동 폭
$28.66
$95.11
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
91.88 | 9.86B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill
Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case - Law360
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors - Seeking Alpha
Corcept Therapeutics : CORT - 24/7 Wall St.
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com - Investing.com Nigeria
Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings - Stock Titan
Corcept Therapeutics CDO William Guyer sells $1.86m in stock - Investing.com
Insider at Corcept (NASDAQ: CORT) sells shares after option exercise - Stock Titan
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise - Stock Titan
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock - AD HOC NEWS
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept (CORT) executive sells 25K shares after exercising options - Stock Titan
CORTCorcept Therapeutics Inc Options - Finviz
Corcept Therapeutics stock hits 52-week high at 91.1 USD By Investing.com - Investing.com Canada
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report - Sahm
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to book forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com
Corcept gives FDA new relacorilant data in resubmitted application - Cushing's Disease News
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - PR Newswire
Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD - TradingView
Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT) - TradingView
HTD Forecast — Price Target — Prediction for 2027 - TradingView
Corcept Therapeutics Inc (CORT) Institutional Confidence - TradingKey
Corcept Therapeutics Inc (CORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan - Stock Titan
Corcept (CORT) director’s entities report 20K-share sale and large holdings - Stock Titan
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome - Business Wire
Corcept Therapeutics Inc (CORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data - GuruFocus
Corcept Therapeutics (CORT) Resubmits Drug Application for Cushi - GuruFocus
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome - Stock Titan
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):